DA-032 15 (Abilify MyCite 15 mg)
Generic Name: aripiprazole
Pill with imprint DA-032 15 is Yellow, Round and has been identified as Abilify MyCite 15 mg. It is supplied by Otsuka Pharmaceutical Co., Ltd.
Abilify MyCite is used in the treatment of bipolar disorder; depression; schizophrenia and belongs to the drug class atypical antipsychotics. Risk cannot be ruled out during pregnancy. Abilify MyCite 15 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for DA-032 15
Abilify MyCite
- Generic Name
- aripiprazole
- Imprint
- DA-032 15
- Strength
- 15 mg
- Color
- Yellow
- Size
- 6.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Atypical antipsychotics
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Otsuka Pharmaceutical Co., Ltd
- National Drug Code (NDC)
- 59148-0032
- Inactive Ingredients
-
corn starch,
lactose monohydrate,
magnesium stearate,
microcrystalline cellulose,
ferric oxide yellow,
ferric oxide red,
FD&C Blue No. 2,
aluminum oxide,
aluminum,
magnesium,
silicon,
silicon dioxide,
titanium,
triethyl citrate
Note: Inactive ingredients may vary.
More about Abilify MyCite (aripiprazole)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Drug class: atypical antipsychotics
- FDA Alerts (4)
- FDA Approval History
Consumer resources
- Other brands
- Aristada, Aristada Initio, Abilify Discmelt
Professional resources
Other Formulations
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.